3 Quantum Stocks Just Scored $100 Million in Government Funding. Which Is the Best to Buy Now?

Rigetti, D-Wave, and Quantinuum each received $100 million in U.S. CHIPS Act funding to advance quantum computing, with Rigetti and D-Wave providing government equity stakes while Quantinuum did not. Rigetti's superconducting systems are roughly 10,000x faster than trapped-ion systems but reported 99.1% two-qubit fidelity, versus Quantinuum's 99.92% and its 99.999% logical-fidelity target for its Sol system next year. The article favors Quantinuum, citing its accuracy leadership, software stack, Honeywell backing, and growing revenue, while noting D-Wave's gate-model ambitions remain early-stage.

Analysis

The funding structure matters more than the headline amount: equity-linked government support lowers near-term financing risk for RGTI and QBTS but likely embeds dilution, warrant overhang, and milestone scrutiny precisely when both will need repeated capital raises. That creates an asymmetric competitive advantage for QNT/HON if its support is non-dilutive and its industrial supply chain can convert technical leadership into contracted capacity. Over 6-18 months, the relevant differentiator is not raw qubit count or speed but the physical-qubit overhead required for a usable logical qubit; a modest fidelity gap can translate into orders-of-magnitude differences in hardware, power, and customer operating cost.

GFS is a quieter beneficiary if ion-trap production moves from bespoke fabrication toward qualified 300mm processes: quantum revenue will be immaterial initially, but qualification expands GFS's strategic-foundry narrative and creates follow-on defense/customer credibility. Conversely, QBTS's commercial annealing franchise may support earlier revenue, yet it risks being valued as a broad quantum-platform winner before gate-model economics and error-correction benchmarks are externally validated. The near-term tradeable catalyst is milestone disclosure and customer bookings over the next 1-3 quarters; the structural catalyst is independently verified logical fidelity and repeatable system uptime over 6-18 months.

Consensus is likely over-rewarding government validation as proof of technical convergence. Subsidies can extend the runway of technically weaker architectures rather than identify the eventual winner, so the highest-beta names remain vulnerable to 20-40% drawdowns on missed fidelity, cash-burn, or dilution milestones. A credible QNT logical-fidelity demonstration, or evidence that QBTS/RGTI can materially close the error-rate gap without sharply worsening yield and refrigeration cost, would falsify the relative-quality thesis.

Key Decisions for Investors

• Prefer a 6-12 month quality pair: long QNT (or HON if QNT equity/security access is not independently investable) versus short a basket of QBTS and RGTI. Size modestly given correlated quantum beta; target 15-25% relative outperformance, with exit if QBTS/RGTI publish independently validated error-correction milestones or QNT misses its next logical-fidelity timetable.
• Treat QBTS and RGTI as event-driven trading vehicles, not core longs: wait for post-funding documentation that specifies dilution, government ownership rights, and technical milestones before adding exposure. A financing that increases fully diluted shares materially, or quarterly cash burn that shortens runway below 18 months, is a short/avoid trigger.
• Accumulate GFS only on weakness as a second-order supplier watch, rather than buying for near-term quantum revenue. Reassess after foundry qualification, wafer-volume commitments, or defense-related customer awards; absent those disclosures, the quantum contribution is unlikely to move estimates within the next 12 months.
• For long-only quantum exposure, require evidence of paid commercial bookings, renewal rates, and gross-margin progression rather than benchmark claims. If quarterly bookings remain research-driven while operating losses expand, reduce sector exposure despite positive technical announcements.